EBS
NYSE · Biotechnology
Emergent Biosolutions Inc
$5.90
-0.35 (-5.60%)
Open$6.43
Previous Close$6.25
Day High$6.47
Day Low$5.78
52W High$14.06
52W Low$4.36
Volume—
Avg Volume1.03M
Market Cap366.09M
P/E Ratio—
EPS$-3.51
SectorBiotechnology
Analyst Ratings
Buy
7 analysts
Price Target
+359.0% upside
Current
$5.90
$5.90
Target
$27.08
$27.08
$18.81
$27.08 avg
$37.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 681.34M | 781.44M | 356.03M |
| Net Income | 48.24M | 49.80M | -80,261,545 |
| Profit Margin | 7.1% | 6.7% | -22.5% |
| EBITDA | 140.32M | 152.89M | -95,339,299 |
| Free Cash Flow | — | — | -67,766,487 |
| Rev Growth | -12.8% | -12.8% | +7.9% |
| Debt/Equity | 1.09 | 1.09 | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |